featured
Brentuximab Vedotin Improves Outcomes in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Five-Year Results of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Blood 2017 Oct 03;[EPub Ahead of Print], B Pro, R Advani, P Brice, NL Bartlett, JD Rosenblatt, T Illidge, J Matous, R Ramchandren, M Fanale, JM Connors, K Fenton, D Huebner, JM Pinelli, DA Kennedy, A ShustovFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.